Skip to main content
Back to News
Multiply Labs is scaling robotics-driven biomanufacturing to industrialize cell therapy production.
Technology
1 min read

Multiply Labs is scaling robotics-driven biomanufacturing to industrialize cell therapy production.

The AMW Read

The article updates the player map for Vertical AI (Healthcare/Bio) by demonstrating a high-impact convergence of Robotics (Segment 10) and biomanufacturing to drive significant cost reduction.
NoveltySignificance
Healthcare & Bio Β· Player MapRobotics Β· Player Map

Multiply Labs is scaling robotics-driven biomanufacturing to industrialize cell therapy production. By integrating NVIDIA Physical AI and GR00T models, the company has reduced manufacturing costs by 70%, lowering per-dose expenses from $100,000 to approximately $25,000. This automation increases throughput 100-fold per square foot while eliminating human contamination risks. This transition from manual labs to autonomous robotic clusters marks a systemic shift in making life-saving treatments globally accessible. πŸ§¬πŸ€–

#Biotech #Robotics #NVIDIA #AI #Biomanufacturing

Read Original

How This Connects

Based on Healthcare & Bio Β· Player Map

  1. 5d agoAnthropic releases Claude Science Beta, a multi-agent AI workbench designed to run end-to-end resear...Anthropic
  2. 6d agoBaiyao Tech (η™Ύζ›œη§‘ζŠ€) releases AURA CellOS, first AI virtual cell based on LLM-JEPA architecture.η™Ύζ›œη§‘ζŠ€
  3. 6d agoAnthropic wants to develop its own drugs. At an event called β€œThe Briefing: AI for Science,” the com...Anthropic
  4. 1w agoAnthropic launches Claude Science AI workbench for life sciences researchAnthropic
  5. 5mo agoMultiply Labs is scaling robotics-driven biomanufacturing to industrialize cell therapy production. Β· THIS ARTICLE

Related News

Discover AI Startups

Explore 2,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard